

SENATE BILL No. 132

DIGEST OF INTRODUCED BILL

Citations Affected: IC 35-31.5-2-321.

Synopsis: Synthetic drugs. Removes mitragynine and 7-hydroxymitragynine from the definition of "synthetic drug".

Effective: July 1, 2013.

Kruse

January 7, 2013, read first time and referred to Committee on Corrections & Criminal Law.

C
o
p
y



First Regular Session 118th General Assembly (2013)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2012 Regular Session of the General Assembly.

C
o
p
y

SENATE BILL No. 132

A BILL FOR AN ACT to amend the Indiana Code concerning criminal law and procedure.

Be it enacted by the General Assembly of the State of Indiana:

1 SECTION 1. IC 35-31.5-2-321, AS ADDED BY P.L.114-2012,
2 SECTION 67, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3 JULY 1, 2013]: Sec. 321. "Synthetic drug" means:
4 (1) a substance containing one (1) or more of the following
5 chemical compounds, including an analog of the compound:
6 (A) JWH-015 ((2-Methyl-1-propyl-1H-
7 indol-3-yl)-1-naphthalenylmethanone).
8 (B) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).
9 (C) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).
10 (D) JWH-073
11 (naphthalen-1-yl-(1-butylindol-3-yl)methanone).
12 (E) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol-
13 3-yl)methanone).
14 (F) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
15 (G) JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)-
16 naphthalen-1-yl-methanone).
17 (H) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).



- 1 (I) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).
 2 (J) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).
 3 (K) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-
 4 3-(2-methyloctan-2-yl)-
 5 6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol).
 6 (L) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-
 7 3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo
 8 [c]chromen-1-ol).
 9 (M) HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-
 10 (2-methyloctan-2-yl)phenyl]-
 11 7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
 12 (N) HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6-
 13 (1-methylethenyl)-2-cyclohexen-1-yl]-5
 14 -pentyl-2,5-cyclohexadiene-1,4-dione).
 15 (O) CP 55,940
 16 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-
 17 5-(2-methyloctan-2-yl)phenol).
 18 (P) CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]-5-
 19 (2-methyloctan-2-yl)phenol) and its homologues, or
 20 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)
 21 phenol, where side chain n=5, and homologues where side
 22 chain n=4, 6, or 7.
 23 (Q) WIN 55212-2
 24 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
 25 pyrrolo [1,2,3-de)-1,4-benzoxazin-
 26 6-yl]-1-naphthalenylmethanone).
 27 (R) RCS-4 ((4-methoxyphenyl)
 28 (1-pentyl-1H-indol-3-yl)methanone).
 29 (S) RCS-8 (1-(1-(2-cyclohexylethyl)-1H-
 30 indol-3-yl)-2-(2-methoxyphenyl)ethanone).
 31 (T) 4-Methylmethcathinone. Other name: mephedrone.
 32 (U) 3,4-Methylenedioxymethcathinone. Other name:
 33 methylone.
 34 (V) Fluoromethcathinone.
 35 (W) 4-Methoxymethcathinone. Other name: methedrone.
 36 (X) 4-Ethylmethcathinone (4-EMC).
 37 (Y) Methylenedioxyprovalerone. Other name: MDPV.
 38 (Z) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.
 39 (AA) JWH-098, or
 40 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.
 41 (BB) JWH-164, or
 42 1-pentyl-3-(7-methoxy-1-naphthoyl)indole.

C
O
P
Y

- 1 (CC) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.
 2 (DD) JWH-201, or
 3 1-pentyl-3-(4-methoxyphenylacetyl)indole.
 4 (EE) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.
 5 (FF) AM-694, or
 6 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
 7 (GG) CP 50,556-1, or
 8 [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpe
 9 ntan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1
 10 -yl] acetate.
 11 (HH) Dimethylheptylpyran, or DMHP.
 12 (II) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP.
 13 (JJ) 6-APB [6-(2-aminopropyl)benzofuran].
 14 ~~(LL)~~ 7-hydroxymitragynine.
 15 ~~(MM)~~ (KK) α -PPP [α -pyrrolidinopropiophenone].
 16 ~~(NN)~~ (LL) α -PVP (desmethylpyrovalerone).
 17 ~~(OO)~~ (MM) AM-251.
 18 ~~(PP)~~ (NN) AM-1241.
 19 ~~(QQ)~~ (OO) AM-2201.
 20 ~~(RR)~~ (PP) AM-2233.
 21 ~~(SS)~~ (QQ) Buphedrone.
 22 ~~(TT)~~ (RR) Butylone.
 23 ~~(UU)~~ (SS) CP-47,497-C7.
 24 ~~(VV)~~ (TT) CP-47,497-C8.
 25 ~~(WW)~~ (UU) Desoxypipradol.
 26 ~~(XX)~~ (VV) Ethylone.
 27 ~~(YY)~~ (WW) Eutylone.
 28 ~~(ZZ)~~ (XX) Flephedrone.
 29 ~~(AAA)~~ (YY) JWH-011.
 30 ~~(BBB)~~ (ZZ) JWH-020.
 31 ~~(CCC)~~ (AAA) JWH-022.
 32 ~~(DDD)~~ (BBB) JWH-030.
 33 ~~(EEE)~~ (CCC) JWH-182.
 34 ~~(FFF)~~ (DDD) JWH-302.
 35 ~~(GGG)~~ (EEE) MDAI [5,6-methylenedioxy-2-aminoindane].
 36 ~~(HHH)~~ Mitragynine.
 37 ~~(III)~~ (FFF) Naphyrone.
 38 ~~(JJJ)~~ (GGG) Pentedrone.
 39 ~~(LLL)~~ (HHH) Pentylone.
 40 ~~(MMM)~~ (III) Methoxetamine
 41 [2-(3-methoxyphenyl)-2-(ethylamino)-cyclohexanone].
 42 (2) Any compound structurally derived from

C
o
p
y

- 1 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by
2 substitution at the nitrogen atom of the indole ring by alkyl,
3 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
4 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
5 group, whether or not further substituted in the indole ring to any
6 extent and whether or not substituted in the naphthyl ring to any
7 extent.
- 8 (3) Any compound structurally derived from 3-(1-naphthoyl)
9 pyrrole by substitution at the nitrogen atom of the pyrrole ring by
10 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
11 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
12 group, whether or not further substituted in the pyrrole ring to any
13 extent and whether or not substituted in the naphthyl ring to any
14 extent.
- 15 (4) Any compound structurally derived from
16 1-(1-naphthylmethyl)indene by substitution at the 3-position of
17 the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
18 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
19 2-(4-morpholinyl)ethyl group, whether or not further substituted
20 in the indene ring to any extent and whether or not substituted in
21 the naphthyl ring to any extent.
- 22 (5) Any compound structurally derived from 3-phenylacetylindole
23 by substitution at the nitrogen atom of the indole ring with alkyl,
24 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
26 group, whether or not further substituted in the indole ring to any
27 extent and whether or not substituted in the phenyl ring to any
28 extent.
- 29 (6) Any compound structurally derived from
30 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position
31 of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
32 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
33 2-(4-morpholinyl)ethyl group, whether or not substituted in the
34 cyclohexyl ring to any extent.
- 35 (7) Any compound containing a 3-(benzoyl)indole structure with
36 substitution at the nitrogen atom of the indole ring by alkyl,
37 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
38 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
39 group, whether or not further substituted in the indole ring to any
40 extent and whether or not substituted in the phenyl ring to any
41 extent.
- 42 (8) Any compound, except bupropion or a compound listed under

C
O
P
Y

- 1 a different schedule, structurally derived from
2 2-aminopropan-1-one by substitution at the 1-position with either
3 phenyl, naphthyl, or thiophene ring systems, whether or not the
4 compound is further modified:
- 5 (A) by substitution in the ring system to any extent with alkyl,
6 alkylendioxy, alkoxy, haloalkyl, hydroxyl, or halide
7 substituents, whether or not further substituted in the ring
8 system by one or more other univalent substituents;
- 9 (B) by substitution at the 3-position with an acyclic alkyl
10 substituent;
- 11 (C) by substitution at the 2-amino nitrogen atom with alkyl,
12 dialkyl, benzyl, or methoxybenzyl groups; or
- 13 (D) by inclusion of the 2-amino nitrogen atom in a cyclic
14 structure.
- 15 (9) Any compound determined to be a synthetic drug by rule
16 adopted under IC 25-26-13-4.1.

C
o
p
y